Cargando…
Definition of the viral targets of protective HIV-1-specific T cell responses
BACKGROUND: The efficacy of the CTL component of a future HIV-1 vaccine will depend on the induction of responses with the most potent antiviral activity and broad HLA class I restriction. However, current HIV vaccine designs are largely based on viral sequence alignments only, not incorporating exp...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292987/ https://www.ncbi.nlm.nih.gov/pubmed/22152067 http://dx.doi.org/10.1186/1479-5876-9-208 |
_version_ | 1782225346007924736 |
---|---|
author | Mothe, Beatriz Llano, Anuska Ibarrondo, Javier Daniels, Marcus Miranda, Cristina Zamarreño, Jennifer Bach, Vanessa Zuniga, Rosario Pérez-Álvarez, Susana Berger, Christoph T Puertas, Maria C Martinez-Picado, Javier Rolland, Morgane Farfan, Marilu Szinger, James J Hildebrand, William H Yang, Otto O Sanchez-Merino, Victor Brumme, Chanson J Brumme, Zabrina L Heckerman, David Allen, Todd M Mullins, James I Gómez, Guadalupe Goulder, Philip J Walker , Bruce D Gatell, Jose M Clotet, Bonaventura Korber, Bette T Sanchez, Jorge Brander, Christian |
author_facet | Mothe, Beatriz Llano, Anuska Ibarrondo, Javier Daniels, Marcus Miranda, Cristina Zamarreño, Jennifer Bach, Vanessa Zuniga, Rosario Pérez-Álvarez, Susana Berger, Christoph T Puertas, Maria C Martinez-Picado, Javier Rolland, Morgane Farfan, Marilu Szinger, James J Hildebrand, William H Yang, Otto O Sanchez-Merino, Victor Brumme, Chanson J Brumme, Zabrina L Heckerman, David Allen, Todd M Mullins, James I Gómez, Guadalupe Goulder, Philip J Walker , Bruce D Gatell, Jose M Clotet, Bonaventura Korber, Bette T Sanchez, Jorge Brander, Christian |
author_sort | Mothe, Beatriz |
collection | PubMed |
description | BACKGROUND: The efficacy of the CTL component of a future HIV-1 vaccine will depend on the induction of responses with the most potent antiviral activity and broad HLA class I restriction. However, current HIV vaccine designs are largely based on viral sequence alignments only, not incorporating experimental data on T cell function and specificity. METHODS: Here, 950 untreated HIV-1 clade B or -C infected individuals were tested for responses to sets of 410 overlapping peptides (OLP) spanning the entire HIV-1 proteome. For each OLP, a "protective ratio" (PR) was calculated as the ratio of median viral loads (VL) between OLP non-responders and responders. RESULTS: For both clades, there was a negative relationship between the PR and the entropy of the OLP sequence. There was also a significant additive effect of multiple responses to beneficial OLP. Responses to beneficial OLP were of significantly higher functional avidity than responses to non-beneficial OLP. They also had superior in-vitro antiviral activities and, importantly, were at least as predictive of individuals' viral loads than their HLA class I genotypes. CONCLUSIONS: The data thus identify immunogen sequence candidates for HIV and provide an approach for T cell immunogen design applicable to other viral infections. |
format | Online Article Text |
id | pubmed-3292987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32929872012-03-05 Definition of the viral targets of protective HIV-1-specific T cell responses Mothe, Beatriz Llano, Anuska Ibarrondo, Javier Daniels, Marcus Miranda, Cristina Zamarreño, Jennifer Bach, Vanessa Zuniga, Rosario Pérez-Álvarez, Susana Berger, Christoph T Puertas, Maria C Martinez-Picado, Javier Rolland, Morgane Farfan, Marilu Szinger, James J Hildebrand, William H Yang, Otto O Sanchez-Merino, Victor Brumme, Chanson J Brumme, Zabrina L Heckerman, David Allen, Todd M Mullins, James I Gómez, Guadalupe Goulder, Philip J Walker , Bruce D Gatell, Jose M Clotet, Bonaventura Korber, Bette T Sanchez, Jorge Brander, Christian J Transl Med Research BACKGROUND: The efficacy of the CTL component of a future HIV-1 vaccine will depend on the induction of responses with the most potent antiviral activity and broad HLA class I restriction. However, current HIV vaccine designs are largely based on viral sequence alignments only, not incorporating experimental data on T cell function and specificity. METHODS: Here, 950 untreated HIV-1 clade B or -C infected individuals were tested for responses to sets of 410 overlapping peptides (OLP) spanning the entire HIV-1 proteome. For each OLP, a "protective ratio" (PR) was calculated as the ratio of median viral loads (VL) between OLP non-responders and responders. RESULTS: For both clades, there was a negative relationship between the PR and the entropy of the OLP sequence. There was also a significant additive effect of multiple responses to beneficial OLP. Responses to beneficial OLP were of significantly higher functional avidity than responses to non-beneficial OLP. They also had superior in-vitro antiviral activities and, importantly, were at least as predictive of individuals' viral loads than their HLA class I genotypes. CONCLUSIONS: The data thus identify immunogen sequence candidates for HIV and provide an approach for T cell immunogen design applicable to other viral infections. BioMed Central 2011-12-07 /pmc/articles/PMC3292987/ /pubmed/22152067 http://dx.doi.org/10.1186/1479-5876-9-208 Text en Copyright ©2011 Mothe et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Mothe, Beatriz Llano, Anuska Ibarrondo, Javier Daniels, Marcus Miranda, Cristina Zamarreño, Jennifer Bach, Vanessa Zuniga, Rosario Pérez-Álvarez, Susana Berger, Christoph T Puertas, Maria C Martinez-Picado, Javier Rolland, Morgane Farfan, Marilu Szinger, James J Hildebrand, William H Yang, Otto O Sanchez-Merino, Victor Brumme, Chanson J Brumme, Zabrina L Heckerman, David Allen, Todd M Mullins, James I Gómez, Guadalupe Goulder, Philip J Walker , Bruce D Gatell, Jose M Clotet, Bonaventura Korber, Bette T Sanchez, Jorge Brander, Christian Definition of the viral targets of protective HIV-1-specific T cell responses |
title | Definition of the viral targets of protective HIV-1-specific T cell responses |
title_full | Definition of the viral targets of protective HIV-1-specific T cell responses |
title_fullStr | Definition of the viral targets of protective HIV-1-specific T cell responses |
title_full_unstemmed | Definition of the viral targets of protective HIV-1-specific T cell responses |
title_short | Definition of the viral targets of protective HIV-1-specific T cell responses |
title_sort | definition of the viral targets of protective hiv-1-specific t cell responses |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292987/ https://www.ncbi.nlm.nih.gov/pubmed/22152067 http://dx.doi.org/10.1186/1479-5876-9-208 |
work_keys_str_mv | AT mothebeatriz definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT llanoanuska definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT ibarrondojavier definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT danielsmarcus definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT mirandacristina definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT zamarrenojennifer definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT bachvanessa definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT zunigarosario definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT perezalvarezsusana definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT bergerchristopht definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT puertasmariac definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT martinezpicadojavier definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT rollandmorgane definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT farfanmarilu definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT szingerjamesj definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT hildebrandwilliamh definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT yangottoo definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT sanchezmerinovictor definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT brummechansonj definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT brummezabrinal definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT heckermandavid definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT allentoddm definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT mullinsjamesi definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT gomezguadalupe definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT goulderphilipj definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT walkerbruced definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT gatelljosem definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT clotetbonaventura definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT korberbettet definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT sanchezjorge definitionoftheviraltargetsofprotectivehiv1specifictcellresponses AT branderchristian definitionoftheviraltargetsofprotectivehiv1specifictcellresponses |